JPMorgan Downgrades Cerevel Therapeutics (CERE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CERE Hot Sheet
Price: $44.96 --0%
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
JPMorgan analyst Jessica Fye downgraded Cerevel Therapeutics (NASDAQ: CERE) from Overweight to Neutral with a price target of $29.00 (from $40.00).
For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.
Shares of Cerevel Therapeutics closed at $24.32 yesterday.
You May Also Be Interested In
- Rosenblatt cuts Roku to Neutral as Fox merger nears closing
- ON Semiconductor (ON) PT Lowered to $87 at Mizuho
- Celanese (CE) PT Raised to $53 at Mizuho
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
